European preclinical CRO bridging early drug discovery to clinical development
Selvita operates a preclinical contract research organization across Europe, serving pharma and biotech clients from early discovery through candidate selection. The tech stack reveals a hybrid operational model: wet-lab infrastructure (cryo-EM, LC-MS, qPCR, HPLC) paired with analytical and data-integration tooling (SQL Server, Power BI, Azure, AWS, Python, Docker, Kubernetes). Active hiring in research roles across Poland and Bulgaria, combined with projects spanning translational oncology platforms, gene-to-structure pipelines, and DMPK strategy execution, suggests expansion of both scientific capacity and internal data infrastructure to accelerate milestone delivery.
Selvita is a preclinical contract research organization and public company based in Kraków, employing 1,001–5,000 people. The company specializes in bridging early-stage drug discovery and preclinical development for pharmaceutical and biotech clients, with capabilities spanning bioanalytical development, bioinformatics, systems biology, genomics, and proteomics. Current projects include translational oncology platforms (colorectal cancer focus), gene-to-structure pipelines, and DMPK strategy integration. The organization operates in Poland and Bulgaria and is actively scaling research capacity while building internal data warehousing and reporting infrastructure.
Selvita operates as a European preclinical contract research organization, providing drug discovery and preclinical development services to pharma and biotech companies, with specialization in bioanalytical development, bioinformatics, genomics, and proteomics.
Selvita uses cryo-EM, LC-MS, HPLC, and qPCR for lab work; SQL Server, Power BI, and SQL Server Analysis Services for analytics; Python, Docker, Kubernetes, and GitLab for engineering; and Azure/AWS for cloud infrastructure, plus AlphaFold and RAG for computational biology.
Other companies in the same industry, closest in size